{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:43:03Z","timestamp":1793508183568,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.breast.2025.104554","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:05:53Z","timestamp":1754424353000},"page":"104554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study"],"prefix":"10.1016","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6344-3544","authenticated-orcid":false,"given":"Leandro Jonata de Carvalho","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Dornelles","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Assad-Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Argolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange Moraes","family":"Sanches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Bines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael Aliosha","family":"Kaliks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"de Melo Gagliato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romualdo","family":"Barroso-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana Strava","family":"Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Kazumi","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Henrique","family":"dos Anjos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudinei","family":"Linck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais Baccili Cury","family":"Megid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Negrini","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Musse","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelle Goldner","family":"Cesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Gaud\u00eancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa Matos Almeida","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Antonio","family":"Pereira de Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata Colombo","family":"Bonadio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenaide","family":"Silva de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Rodrigues","family":"Beal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Machado","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia Telles","family":"Sales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00falia Leal Franco","family":"Parisi Marli\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max Senna","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.breast.2025.104554_bib1","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.breast.2025.104554_bib2","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.breast.2025.104554_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2025.104554_bib4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2025.104554_bib5","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.breast.2025.104554_bib6","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N Engl J Med"},{"issue":"8042","key":"10.1016\/j.breast.2025.104554_bib7","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"issue":"16_suppl","key":"10.1016\/j.breast.2025.104554_bib8","doi-asserted-by":"crossref","first-page":"TPS609","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS609","article-title":"Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+\/HER2- early breast cancer: ADAPTcycle","volume":"40","author":"Harbeck","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2025.104554_bib9","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.2009.24.4798","article-title":"Prediction of risk of distant recurrence using the 21-Gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study","volume":"28","author":"Dowsett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2025.104554_bib10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2016.69.4406","article-title":"Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance)","volume":"35","author":"Ellis","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2025.104554_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10549-017-4358-6","article-title":"Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 west German study group (WSG) PlanB trial","volume":"165","author":"Nitz","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"10.1016\/j.breast.2025.104554_bib12","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.21.02759","article-title":"Endocrine therapy response and 21-Gene expression assay for therapy guidance in HR+\/HER2\u2013 early breast cancer","volume":"40","author":"Nitz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.breast.2025.104554_bib13","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2024.42.16_suppl.540","article-title":"Cancer outcomes from a real-world cohort of patients eligible for adjuvant CDK4\/6 inhibitors but without genomic risk for chemotherapy: a GBECAM multicenter retrospective study","volume":"42","author":"Oliveira","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9_Supplement","key":"10.1016\/j.breast.2025.104554_bib14","doi-asserted-by":"crossref","first-page":"GS03","DOI":"10.1158\/1538-7445.SABCS23-GS03-06","article-title":"Abstract GS03-06: genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial","volume":"84","author":"Turner","year":"2024","journal-title":"Cancer Res"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977625005715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:47:14Z","timestamp":1758588434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977625005715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":14,"alternative-id":["S0960977625005715"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2025.104554","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2025.104554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104554"}}